Hepatitis C virus infection in chronic kidney disease: paradigm shift in management

키워드

참고문헌 (60)

1. Thrift AP, "Global epidemiology and burden of HCV infection and HCV-related disease", Nat Rev Gastroenterol Hepatol, 14, pp.122~132 (2017)[DOI]
2. Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)[DOI]
3. Cacoub P, "Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C", Arthritis Rheum, 42, pp.2204~2212 (1999)[DOI]
4. Cacoub P, "Extrahepatic manifestations of chronic hepatitis C virus infection", Dig Liver Dis, 46(Suppl 5), pp.S165~S173 (2014)[DOI]
5. Cacoub P, "Extrahepatic manifestations of chronic hepatitis C virus infection", Ther Adv Infect Dis, 3, pp.3~14 (2016)
6. Fabrizi F, "Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis", Dig Dis Sci, 60, pp.3801~3813 (2015)[DOI]
7. Park H, "A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection", J Viral Hepat, 22, pp.897~905 (2015)[DOI]
8. Park H, "Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD", Hepatology (2017)
9. 방병기, "신 이식 환자에서 B형과 C형 간염바이러스 감염 환자의 15년간 추적 조사", Kidney Research and Clinical Practice, 21(3), pp.423~434 (2002), 대한신장학회
10. Fabrizi F, "Meta-analysis of observational studies: hepatitis C and survival after renal transplant", J Viral Hepat, 21, pp.314~324 (2014)[DOI]
11. Scott DR, "Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand", Transplantation, 90, pp.1165~1171 (2010)[DOI]
12. Fried MW, "Side effects of therapy of hepatitis C and their management", Hepatology, 36(5 Suppl 1), pp.S237~S244 (2002)
13. Rostaing L, "Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications", J Am Soc Nephrol, 9, pp.2344~2348 (1998)
14. Lee JJ, "Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis", PLoS One, 9, pp.e100790~ (2014)[DOI]
15. Chen YC, "A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease", Kidney Int, 85, pp.1200~1207 (2014)[DOI]
16. Bose SK, "Hepatitis C virus infection and insulin resistance", World J Diabetes, 5, pp.52~58 (2014)[DOI]
17. Fabrizi F, "Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies", Am J Transplant, 5, pp.2433~2440 (2005)[DOI]
18. Villar LM, "High prevalence of insulin resistance among Brazilian chronic hepatitis C patients", Arch Endocrinol Metab, 61, pp.628~632 (2017)[DOI]
19. Kawaguchi T, "Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3", Am J Pathol, 165, pp.1499~1508 (2004)[DOI]
20. Bose SK, "Hepatitis C virus activates the mTOR", S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance, 2012, pp.86, 6315~6322
21. Shoko Horita, "The role of renal proximal tubule transport in the regulation of blood pressure", Kidney Research and Clinical Practice, 36(1), pp.12~21 (2017), 대한신장학회
22. Olson AL, "Regulation of GLUT4 expression in vivo and in vitro", Front Biosci, 8, pp.s401~s409 (2003)[DOI]
23. Sciacqua A, "Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance", Intern Emerg Med, 11, pp.553~559 (2016)[DOI]
24. Schamberg NJ, "Hepatitis C virus-related mixed cryoglobulinemia: pathogenesis, clinica manifestations, and new therapies", Gastroenterol Hepatol (N Y), 3, pp.695~703 (2007)
25. Curry MP, "Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver", J Hepatol, 38, pp.642~650 (2003)
26. Ozkok A, "Hepatitis C virus associated glomerulopathies", World J Gastroenterol, 20, pp.7544~7554 (2014)[DOI]
27. Baid S, "Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients", J Am Soc Nephrol, 10, pp.146~153 (1999)
28. Markowitz GS, "Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy", J Am Soc Nephrol, 9, pp.2244~2252 (1998)
29. Roccatello D, "Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis", Am J Kidney Dis, 49, pp.69~82 (2007)[DOI]
30. El-Serag HB, "Extrahepatic manifestations of hepatitis C among United States male veterans", Hepatology, 36, pp.1439~1445 (2002)[DOI]
31. Liangpunsakul S, "Relationship between hepatitis C and microalbuminuria: results from the NHANES III", Kidney Int, 67, pp.285~290 (2005)[DOI]
32. Fissell RB, "Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS", Kidney Int, 65, pp.2335~2342 (2004)[DOI]
33. Johnson DW, "Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data", Nephrol Dial Transplant, 24, pp.1598~1603 (2009)[DOI]
34. Finelli L, "National surveillance of dialysis-associated diseases in the United States, 2002", Semin Dial, 18, pp.52~61 (2005)[DOI]
35. 박혜인, "Korean clinical practice guidelines for preventing the transmission of infections in hemodialysis facilities", Kidney Research and Clinical Practice, 37(1), pp.8~19 (2018), 대한신장학회
36. Ayman Karkar, "Infection control guidelines in hemodialysis facilities", Kidney Research and Clinical Practice, 37(1), pp.1~3 (2018), 대한신장학회
37. Nakayama E, "Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy", J Am Soc Nephrol, 11, pp.1896~1902 (2000)
38. Kalantar-Zadeh K, "Hepatitis C virus and death risk in hemodialysis patients", J Am Soc Nephrol, 18, pp.1584~1593 (2007)[DOI]
39. Goodkin DA, "Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis", Clin J Am Soc Nephrol, 12, pp.287~297 (2017)[DOI]
40. Pereira BJ, "Hepatitis C virus infection in dialysis and renal transplantation", Kidney Int, 51, pp.981~999 (1997)[DOI]
41. Kasiske BL, "Diabetes mellitus after kidney transplantation in the United States", Am J Transplant, 3, pp.178~185 (2003)[DOI]
42. 최유경, "Tacrolimus를 근간으로 한 면역억제제를 복용하는 장이식 환자에서 이식 후 새로 발생한 당뇨병의 위험인자", Kidney Research and Clinical Practice, 29(6), pp.761~767 (2010), 대한신장학회
43. Peev V, "Diabetes mellitus in the transplanted kidney", Front Endocrinol (Lausanne), 5, pp.141~ (2014)
44. Rodrigo E, "Newonset diabetes after kidney transplantation: risk factors", J Am Soc Nephrol, 17(12 Suppl 3), pp.S291~S295 (2006)[DOI]
45. Davidson J, "New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003", Transplantation, 75(10 Suppl), pp.SS3~SS24 (2003)
46. Hammoud H, "Glomerular disease during HCV infection in renal transplantation", Nephrol Dial Transplant, 11(Suppl 4), pp.54~55 (1996)
47. Cruzado JM, "Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts", J Am Soc Nephrol, 7, pp.2469~2475 (1996)
48. Cosio FG, "Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation", Kidney Int, 91, pp.304~314 (2017)[DOI]
49. Rendina M, "The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant", J Hepatol, 46, pp.768~774 (2007)[DOI]
50. Liu CH, "Pegylated interferon-<TEX>${\alpha}2a$<", TEX> with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial, 2013, pp.159, 729~738
51. Liu CH, "Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial", Gut, 64, pp.303~311 (2015)[DOI]
52. Fabrizi F, "Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies", J Viral Hepat, 21, pp.681~689 (2014)[DOI]
53. Mehawej M, "Boceprevir-based triple antiviral therapy for chronic hepatitis c virus infection in kidney-transplant candidates", J Transplant, 2015, pp.159795~ (2015)
54. Kaya S, "Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients", Infect Dis (Lond), 47, pp.658~661 (2015)[DOI]
55. Dumortier J, "Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible", J Clin Virol, 56, pp.146~149 (2013)[DOI]
56. Roth D, "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study", Lancet, 386, pp.1537~1545 (2015)[DOI]
57. Saxena V, "Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function", Liver Int, 36, pp.807~816 (2016)[DOI]
58. Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)[DOI]
59. Gane E, "Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment", N Engl J Med, 377, pp.1448~1455 (2017)[DOI]
60. Reau N, "Glecaprevir", pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection, 2018, ~

관련 논문AI추천